I have no idea what a straight sale of Cotara would be worth right now, or after a successful P3 FDA meeting. There would still be a decent amount of risk involved and a few years before any possible revenue from it. It would be nice to hear something about Cotara soon. Maybe on the 10th. Might just be "still in discussions with the FDA on P3". If that's the case, I'd say they pretty much shelved it for now.
In my mind, management as much as said that they are going to partner to get Bavi the rest of the way, and I'm pretty sure that they will. Everything seems to be pointing that way. They've mentioned "partnership discussions" for years, but the loan and recent statements have put a timeline to it in my opinion. I would be surprised if it wasn't done by year end. I would much prefer they get a deep pocketed partner than try to scrape by and go it alone. Too many pitfalls and various entities jerking them around.
News 
Market Data 
Discover 
